Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Roche discloses CPT-2 inhibitors for the treatment of type 2 diabetes

Dec. 28, 2009

Shire submits BLA to the FDA for Replagal, updates Gaucher disease therapy

Dec. 28, 2009

EMEA recommends withdrawal of benfluorex from the market in E.U.

Dec. 28, 2009

PDL and Lilly sign license agreement for teplizumab and other anti-CD3 molecules

Dec. 24, 2009

CPEX completes enrollment in phase IIa Nasulin trial

Dec. 24, 2009

Insulin secretion stimulators in development Merck KGaA for type 2 diabetes therapy

Dec. 24, 2009

Novel GK activators for the treatment of diabetes presented by Roche

Dec. 24, 2009

Bristol-Myers Squibb claims DGAT-1 inhibitors for the treatment of obesity

Dec. 24, 2009

Cardium reports results from 10-year follow-up study of diabetic patients with foot ulcer

Dec. 23, 2009

European CHMP recommends marketing authorization of Amgen's Prolia for osteoporosis

Dec. 23, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...